These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 10563108)

  • 1. [Levofloxacin for prevalent infections in primary care medicine].
    Redondo Sánchez J
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():29-33. PubMed ID: 10563108
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharma-clinics. The drug of the month. Levofloxacin (Tavanic)].
    Scheen AJ
    Rev Med Liege; 2000 Nov; 55(11):1015-7. PubMed ID: 11195704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The first 'respiration' fluoroquinolone--levofloxacin (Tavanic) in therapy of bacterial infections. Pharmacodynamics principles in optimization of administration regimens].
    Budanov SV; Vasil'ev AN; Smirnova LB
    Antibiot Khimioter; 2001; 46(7):38-46. PubMed ID: 11697244
    [No Abstract]   [Full Text] [Related]  

  • 4. The fluoroquinolones after ciprofloxacin and ofloxacin.
    Hooper DC
    Curr Clin Top Infect Dis; 2000; 20():63-91. PubMed ID: 10943519
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of the fluoroquinolones in primary care practice.
    Harding GK
    Clin Invest Med; 1989 Feb; 12(1):71-3. PubMed ID: 2920484
    [No Abstract]   [Full Text] [Related]  

  • 6. [Evaluation of levofloxacin susceptibility against strains isolated from lower urinary tract infections in the community].
    Weber P; Dib C; Durand C; Moniot-Ville N
    Pathol Biol (Paris); 2005 Mar; 53(2):125-8. PubMed ID: 15708658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous followed by oral ofloxacin in the treatment of community acquired lower respiratory tract infections in adults requiring hospitalisation.
    Liam CK; Aziah AM; Lim KH; Wong CM
    Med J Malaysia; 2000 Sep; 55(3):304-7. PubMed ID: 11200708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Criteria for use of ofloxacin and lomefloxacin in adult inpatients and outpatients.
    Spivey IM
    Clin Pharm; 1993 Jun; 12(6):452-8. PubMed ID: 8403817
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment in general practice. Effective, well tolerated therapy].
    MMW Fortschr Med; 2000 Sep; 142(37):58-9. PubMed ID: 11026226
    [No Abstract]   [Full Text] [Related]  

  • 10. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
    Sollet JP
    Int J Antimicrob Agents; 2006 Sep; 28 Suppl 2():S113-4. PubMed ID: 16904296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical experience of levofloxacin in community acquired pneumonia].
    Arancibia F; Maldonado A; Torres A
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():14-8. PubMed ID: 10563105
    [No Abstract]   [Full Text] [Related]  

  • 12. [The present and future of levofloxacin in the treatment of respiratory infections].
    García-Rodríguez JA; Muñoz Bellido JL; Alonso Manzanares MA; Gutiérrez Zufiaurre MN
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():53-8. PubMed ID: 10563113
    [No Abstract]   [Full Text] [Related]  

  • 13. [Levofloxacin and other antibacterial drugs].
    Ivanov DV; Budanov SV
    Antibiot Khimioter; 2006; 51(6):27-37. PubMed ID: 17523419
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral levofloxacin in the treatment of community-acquired pneumonia.
    Nicodemo AC; Lima Nicodemo E; Idrahim KY
    Braz J Infect Dis; 2000 Apr; 4(2):61-6. PubMed ID: 10795070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescribing considerations in fluoroquinolone therapy.
    Gentry LO
    Pharmacotherapy; 1993; 13(2 Pt 2):39S-44S. PubMed ID: 8474937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical role of the quinolones today and in the future.
    Waldvogel FA
    Eur J Clin Microbiol Infect Dis; 1989 Dec; 8(12):1075-9. PubMed ID: 2620674
    [No Abstract]   [Full Text] [Related]  

  • 17. [Antimicrobial drugs for adults in outpatient clinics].
    Valtonen M
    Duodecim; 1991; 107(10):843-9. PubMed ID: 1364727
    [No Abstract]   [Full Text] [Related]  

  • 18. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
    Hutchinson J
    N Engl J Med; 2002 Jul; 347(1):65-7; author reply 65-7. PubMed ID: 12102064
    [No Abstract]   [Full Text] [Related]  

  • 19. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
    Cantón R; Lode H; Graninger W; Milkovich G
    Int J Antimicrob Agents; 2006 Sep; 28 Suppl 2():S115-27. PubMed ID: 16904873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effects and bronchoalveolar transfer of levofloxacin in patients with community-acquired pneumonia.
    Lin Y; Su W; Xu Z; Bai Y
    Chin Med J (Engl); 2001 Feb; 114(2):212-3. PubMed ID: 11780213
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.